Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, has announced the launch of its new Bacterial DNA Residue Assay Kits (qPCR) for researchers to detect and quantify trace amounts of bacterial DNA contamination in a wide range of biopharmaceutical products, ensuring the highest standards of safety and quality.
Bacterial DNA residue assay kits (qPCR) are essential for maintaining the highest levels of product integrity and compliance in the biopharmaceutical industry. As an expert in bioprocess impurity analysis, Creative Diagnostics offers a range of Bacterial DNA Residue (qPCR) assay kits for the detection of trace levels of bacterial DNA contamination in biopharmaceutical products. By effectively monitoring for bacterial DNA contamination, these assay kits prevent potential adverse effects and ensure that the final product is safe for human use.
These kits use advanced quantitative PCR (qPCR) technology with high sensitivity and specificity to reliably identify and quantify bacterial DNA residues. This is essential to ensure the safety and efficacy of biologics, vaccines and other pharmaceuticals. In addition, each kit comes with pre-optimized reagents and comprehensive instructions for seamless integration into existing laboratory protocols. The rapid and accurate results provided by these kits help manufacturers meet stringent regulatory standards and maintain strict quality control throughout the manufacturing process.
For example, the E. coli DNA Residue Assay Kit (Cat. No. DDNA-021) uses PCR fluorescent probe technology to quantitatively detect residual E. coli DNA in samples. This kit provides rapid, highly specific and reliable detection with a minimum detection limit of fg levels. It contains a quantitative E. coli DNA reference standard and is used in conjunction with Creative Diagnostics Host Cell DNA Prep Kit to accurately determine the amount of residual E. coli DNA in biological samples.
The routine testing method for mycobacteria, the culture method, is time-consuming and does not meet the testing requirements of short-life biological products. To address this limitation, the ResDetFast™ Mycobacterium DNA Assay Kit (Cat. No. DDNAF-002), a quantitative fluorescence PCR-based assay designed with primers and probes, targets conserved Mycobacterium sequences for rapid and qualitative detection of Mycobacterium DNA in various biological products, including intermediates, semi-finished and finished products. When used in conjunction with Creative Diagnostics Nucleic Acid Extraction or Purification Kit, this kit can detect Mycobacterium DNA at the 10 CFU level in as little as 1.5 hours.
Creative Diagnostics is committed to providing innovative solutions that support the biopharmaceutical industry. By utilizing these advanced kits, biopharmaceutical manufacturers can proactively monitor and control bacterial contamination, safeguarding the integrity of their products and protecting public health. For more information on Bacterial DNA Residue Assay Kits (qPCR) or project-specific Host Cell DNA Assay Kit development services, please visit https://qbd.creative-diagnostics.com/products/bacterial-dna-residue-assay-kits-qpcr-2792.html.
About Creative Diagnostics
Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.
Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email: Send Email
State: New York
Country: United States
Website: https://qbd.creative-diagnostics.com/